Certificate of Analysis for NR-51612

Pseudomonas aeruginosa, Strain MRSN 435288

Catalog No. NR-51612

This reagent is the tangible property of the U.S. Government.

Product Description:

Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 435288 was isolated in 2016 from a human sputum sample as part of a surveillance program in the United States. *P. aeruginosa*, strain MRSN 435288 was deposited as sensitive to amikacin, aztreonam, ceftazidime, cefepime, piperacillin/tazobactam, meropenem, and tobramycin, intermediately resistant to imipenem, gentamicin and resistant to levofloxacin and ciprofloxacin.

Lot: 70025130[1] **Manufacturing Date: 02AUG2019**

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology[2]	Report results	Circular, convex, entire, glistening and cream (Figure 1)
Motility (wet mount)	Report results	Motile
VITEK® 2 (GN card)	*P. aeruginosa* (≥ 89%)	*P. aeruginosa* (98%)
Antibiotic Susceptibility Profile[3]		
VITEK® (AST-GN81 Card)		
Ampicillin	Report results	Resistant (≥ 32 µg/mL)
Amoxicillin/clavulanic Acid	Report results	Resistant (≥ 32 µg/mL)
Piperacillin/tazobactam	Sensitive	Sensitive (≤ 4 µg/mL)
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Sensitive	Sensitive (≤ 1 µg/mL)
Ceftriaxone	Report results	Intermediate (8-16 µg/mL)
Cefepime	Sensitive	Sensitive (2 µg/mL)
Meropenem	Sensitive	Sensitive (≤ 0.25 µg/mL)
Amikacin	Sensitive	Intermediate (32 µg/mL)[4]
Gentamicin	Intermediate	Sensitive (4 µg/mL)[4]
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Ciprofloxacin	Resistant	Inconclusive[5]
Levofloxacin	Resistant	Intermediate (4 µg/mL)[4]
Tetracycline	Report results	Resistant (≥ 16 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 µg/mL)
Trimethoprim/sulfamethoxazole	Report results	≥ 320 µg/mL[6]
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1420 base pairs)	≥ 99% sequence identity to *P. aeruginosa*, strain MRSN 435288 (GenBank: RXTW01000106.1)	100% sequence identity to *P. aeruginosa*, strain MRSN 435288 (GenBank: RXTW01000106.1)
Purity (post-freeze)[7]	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze)[2]	Growth	Growth

[1]NR-51612 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.
[2]1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar
[3]Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
[4]Susceptibilty results for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.
[5]*P. aeruginosa*, strain MRSN 435288 was deposited as resistant to ciprofloxacin. Repeated antibiotic susceptibility testing determined that for strain MRSN 435288, the ciprofloxacin MICs are 1 µg/mL and 2 µg/mL, which are interpreted as sensitive and intermediate, respectively.
[6]Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa*." Antimicrob. Agents Chemother. 40 (1996): 2288-2290. PubMed: 9036831.

[7]Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with and without 5% CO_2 on Tryptic Soy agar.

Figure 1: Colony Morphology



/Heather Couch/
Heather Couch 28 OCT 2019
Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898